Microtubule-Targeting Anticancer Therapeutics

The field of microtubule-targeting anticancer therapeutics has matured into one of the most effective strategies for halting malignant cell proliferation. Microtubules, assembled from α- and β-tubulin heterodimers, are integral to mitotic spindle formation, intracellular transport and cell migration. Agents that interfere with microtubule dynamics achieve cytostatic and cytotoxic effects by either stabilising or destabilising polymerisation, thus arresting the cell cycle or inducing apoptosis. These include taxanes and epothilones as stabilisers, and vinca alkaloids, colchicine-site binders and novel compounds as destabilisers. Beyond mitotic inhibition, mounting evidence highlights interphase actions such as inhibition of angiogenesis, blockade of cell migration and modulation of innate immune responses. Clinical use of these agents is tempered by dose-limiting neurotoxicity, the emergence of multidrug resistance and limited tumour selectivity. Recent advances focus on novel binding sites, covalent modifiers of α-tubulin, vascular disrupting strategies and combination regimens to overcome resistance. These therapies remain globally significant, demonstrating efficacy across solid tumours and haematological malignancies and offering a platform for next-generation precision treatments.

Research from Nature Portfolio

Structural and mechanistic studies have elucidated new avenues for drug design beyond the classical β-tubulin targets. Covalent binding of a natural product to α-tubulin has been characterised, revealing a Michael addition to a conserved cysteine residue that destabilises microtubules and lays the groundwork for α-tubulin-directed chemotherapeutics. Taxane-site investigation has detailed how a macromolecule engages β-tubulin, locking the nucleotide-binding pocket in a GTP-mimetic state, shifting conformational equilibria to enhance microtubule stability and offering strategies to surmount taxane resistance. In parallel, a lead stilbene derivative has been shown to disrupt tumour vasculature by attenuating key signalling pathways in endothelial cells, inhibiting angiogenesis and reducing microvessel density in vivo, thus demonstrating the therapeutic potential of vascular targeting alongside direct cytoskeletal disruption.

Microtubule-Targeting Anticancer Therapeutics publication trend

The graph below shows the total number of articles in microtubule-targeting anticancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Microtubule: A dynamic, cylindrical polymer of α- and β-tubulin subunits essential for cell division, transport and structural integrity.

Tubulin: The protein building block of microtubules, existing as α- and β-isoforms that form heterodimers.

Microtubule-stabilizing agent (MSA): A compound that promotes tubulin polymerisation and prevents microtubule disassembly.

Microtubule-destabilizing agent (MDA): A compound that binds to tubulin dimers and inhibits microtubule polymerisation.

Chemoresistance: The ability of cancer cells to withstand the cytotoxic effects of chemotherapeutic drugs.

Angiogenesis: The formation of new blood vessels, a process often co-opted by tumours to secure nutrient supply.

References

1. KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules. Developmental Cell (2025).
2. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. Pharmaceuticals (2020).
3. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nature Communications (2016).
4. Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers (2021).
5. The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4. Scientific Reports (2016).
6. Mechanism of microtubule stabilization by taccalonolide AJ. Nature Communications (2017).